I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Non-healing trophic ulcer in Hansen\'s disease patients is one of the major causes for disability. Further, cost involved in the long-term management of such ulcers is substantially high. Minimising the duration of healing can be a major step in the rehabilitation of such patients.

Recent literature shows autologous platelet-rich fibrin matrix (PRFM) being rich in growth factors is effective in the treatment of chronic non-healing leg ulcers.\[[@ref1][@ref2]\] Hence, we studied a series of nine cases showing the usage of autologous PRFM in non-healing chronic trophic ulcers in patients with Hansen\'s disease.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

In the present study, we included seven patients with nine ulcers with the following inclusion and exclusion criteria from January 2015 to May 2015. Ethical clearance was taken from Institutional Ethical Committee.

Inclusion and exclusion criteria {#sec2-1}
--------------------------------

Non-healing trophic ulcers of more than 6 weeks duration in Hansen\'s disease patients who had already been released from treatment were included in the study.

Patients with age group below 18 years, having a history of bleeding disorders, anaemia and other haematological disorders, platelet count \<1.5 Lakhs/cumm, patients on anticoagulant medications (aspirin, warfarin, heparin), uncontrolled diabetes mellitus, with malignant ulcers, pregnant and lactating females were excluded from this study.

Procedure {#sec2-2}
---------

A thorough examination of skin and nerves of patients was carried out to rule out active lesions after taking informed consent. Ulcer size in terms of length, breadth and depth was measured. Primary infection if any was taken care using antibiotics and surgical debridement wherever necessary before starting the treatment. Under strict aseptic precautions, ten ml of venous blood was drawn and added to a sterile centrifugation tube devoid of anticoagulant. Centrifugation was done at 3000 rpm (approximately 400 g) for ten minutes. Three layers were obtained following this: upper straw-coloured platelet poor plasma (PPP), red-coloured lower fraction containing red blood cells (RBCs) and the middle fraction containing the PRFM \[[Figure 1](#F1){ref-type="fig"} -- step 1\]. The upper straw-coloured layer (PPP) was discarded. PRFM was separated from red corpuscles at the base using a sterile forceps and scissor, preserving a small RBC layer measuring around one mm in length, which was transferred onto a sterile gauze. The membrane does not tear when manipulated with forceps and scissor. However, excess force should not be applied. Middle membrane so obtained was compressed between two gauze pieces gently and applied on a healthy wound followed by application of a secondary non-absorbable dressing. Adequate rest was ensured during the treatment course. The secondary dressing of the patient and the dried PRFM was removed from the wound bed after a minimum of 5 days \[[Figure 1](#F1){ref-type="fig"} -- step 6\].

![Procedure steps](JCAS-10-3-g001){#F1}

The procedure was repeated every week up to a maximum of five sittings as per requirement. At the beginning and every week, healing of the ulcer was assessed, area and volume were calculated and photographs were taken. Wound area was calculated using the formula for an ellipse: Length × width × 0.7854 (an ellipse is closer to a wound shape than a square or rectangle). The use of an ellipse for calculating wound measurement has been used in randomised controlled trials in wound healing literature.\[[@ref3][@ref4]\] Volume was calculated using the formula (length × width × 0.7854) × depth.\[[@ref4]\]

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of seven patients with nine ulcers (two patients had two ulcers which were treated simultaneously) were treated with PRFM. The mean age of the patients was 38.33 years. [Table 1](#T1){ref-type="table"} shows an overview of age-sex distribution with reference to wound duration. The sample comprised five male and two female patients. The duration of the ulcer ranged from 2 months to 1 year. Eight of nine ulcers required more than one application of PRFM, with a mean number of three applications. [Table 2](#T2){ref-type="table"} shows details of measurement of ulcers with respect to each sitting. The mean percentage improvement in the area was 93.52%, and volume was 97.74% at the end of the second sitting. All ulcers closed by a maximum of five sittings \[Figures [2](#F2){ref-type="fig"}--[8](#F8){ref-type="fig"}\]. No adjuvant treatment was required for treatment of the ulcers. No adverse events were reported as a result of PRFM treatment. In all cases, it was possible to complete the therapy within 60 min. The volume of ten ml of blood was adequate to cover an ulcer of maximum area 18.85 cm^2^ with 1 mm thickness of PRFM.

###### 

Age sex distribution with reference to wound duration
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###### 

Measurement of ulcers with reference to each sitting
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![Case 1 - Before and after](JCAS-10-3-g004){#F2}
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![Case 6 - Before and after](JCAS-10-3-g009){#F7}

![Case 7 - Before and after](JCAS-10-3-g010){#F8}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Plantar ulceration is one of the most common disability in leprosy and occurs in about 10% of leprosy patients.\[[@ref5]\] By shortening the wound healing phase, the quality of life of these patients can be improved, and they can be rehabilitated at the earliest. Various treatment modalities are available for trophic ulcers such as moist wound dressings, vacuum-assisted closure, hyperbaric oxygen therapy, reconstructive surgeries and topical application of growth factors,\[[@ref6]\] in the form of platelet-rich plasma. Recently, the usefulness of PRFM has been published as a potential and inexpensive means for treatment of ulcers.\[[@ref2]\]

The ulceration found in leprosy is a result of nerve damage and cutaneous anaesthesia and not as a consequence of the infection itself.\[[@ref7]\] Platelets release growth factors and other secretory proteins which influence tissue healing.\[[@ref8]\] It is, therefore, logical to assume, that the presence of more platelets in the wound bed will aid healing. Using purification techniques, the platelet concentration in plasma can be raised to \>1.0 × 10^6^/μl.\[[@ref9]\]

Platelet-rich fibrin (PRF) was first developed by Choukroun *et al*.\[[@ref10]\] in France for use in oral and maxillofacial surgery. PRF belongs to a new generation of platelet concentrates with simplified preparation and without any biochemical blood handling.\[[@ref11]\] This technique neither requires anticoagulant nor bovine thrombin (nor any other gelling agent). It is just centrifuged blood without any addition. The absence of anticoagulant implies the activation in a few minutes of most platelets of the blood sample in contact with the tube walls and the release of the coagulation cascades. Fibrinogen is initially concentrated in the higher part of the tube, before the thrombin transforms it into fibrin clot, which is then concentrated in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma at the top. Platelets are theoretically trapped massively in the fibrin meshes.\[[@ref11]\] Hence, the success of this technique depends on speed of blood collection and transfer to centrifuge which was taken care of in our study.\[[@ref12]\]

A study by Suchetha *et al*. showed that PRP has a higher platelet concentration when compared to PRF.\[[@ref13]\] However, the superior effects of PRF when compared to PRP can be explained on the basis of study by Yazawa *et al*. which showed that, when incorporated into drug delivery systems such as fibrin, the mean concentration of growth factors in the platelet concentrates was three times or more than that observed with conventional platelet-rich plasma. Furthermore, the growth factors were released in a controlled manner over approximately 1 week.\[[@ref14]\] Another study by Dohan *et al*. also proved a slower release of growth factors from PRFM than PRP and observed better healing properties with PRF.\[[@ref15]\] Hence, in our study, we repeated PRFM once a week. In our case series, we achieved a complete closure of all ulcers in a maximum of 5 weeks. In a study by Sarvajnamurthy *et al*. mean duration of the healing of the chronic venous ulcers using PRP was in 5.1 weeks (standard deviation \[SD\] 3.1). The mean percentage improvement in the area and volume of the ulcer was 94.7% (SD 11.12) and 95.6% (SD 10.19) at the end of six sittings.\[[@ref16]\] In our study, in spite of the chronic nature of the wounds, and associated neuropathy, the mean percentage improvement in the area and volume of ulcer at the end of second sitting was 93.52% and 97.74% which was quite significant. Almost similar results were seen in a retrospective study done by Steenvoorde *et al*. on the use of autologous PRF using Vivostat PRF on a range of hard-to-heal wounds. They achieved full closure in eight wounds and a reduction in diameter by up to 66% in three wounds, while the remaining two wounds only showed a reduction in depth with a mean number of 2.2 applications. The mean treatment period was 4.2 weeks with no adverse effects.\[[@ref2]\] However, we could not come across other studies to compare our results of PRFM being used for the treatment of trophic ulcers in treated Hansen\'s disease patients. We could not compare the efficacy of PRP and PRF, but we achieved almost comparable results at the end of two sittings when compared to study a by Sarvajnamurthy *et al*. which took six sittings to achieve it.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

PRFM for the treatment of trophic ulcers is a feasible, safe, simple and inexpensive method. A good patient compliance and satisfaction was seen as there were no problems with application and no complications were reported.
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